{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:23:34Z","timestamp":1791051814710,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.neurobiolaging.2006.07.007","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T22:00:01Z","timestamp":1156543201000},"page":"1637-1643","source":"Crossref","is-referenced-by-count":54,"title":["Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation"],"prefix":"10.1016","volume":"28","author":[{"given":"Federico","family":"Licastro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Porcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Corder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neurobiolaging.2006.07.007_bib1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer's disease, Alzheimer disease cooperative study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib2","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of refecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0531-5565(00)00147-9","article-title":"Density profiles of Alzheimer disease regional brain pathology for the Huddinge Brain Bank: pattern recognition emulates and expands upon Braak staging","volume":"35","author":"Corder","year":"2000","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1155\/JBB.2005.189","article-title":"Cardiovascular damage in Alzheimer disease: autopsy findings from the Bryan ADRC","volume":"2","author":"Corder","year":"2005","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2006.07.007_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/rej.2006.9.56","article-title":"Membership in genetic groups predicts Alzheimer's disease","volume":"9","author":"Corder","year":"2006","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib7","doi-asserted-by":"crossref","unstructured":"Corder EH, Mellcok GD. Parkinson's disease in relation to toxin exposure and mitochondrial complex I gene variants. J Biomed Biotechnol; 2006 Article ID 27601, 8 pages, 2006, in press.","DOI":"10.1155\/JBB\/2006\/27601"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/rej.2006.9.56","article-title":"Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma","volume":"9","author":"Corder","year":"2006","journal-title":"Rejuvenation Res"},{"issue":"3","key":"10.1016\/j.neurobiolaging.2006.07.007_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib10","first-page":"163","article-title":"Neuroinflammation and the genetics of Alzheimer's disease: the search for a pro-inflammatory phenotype","volume":"13","author":"Franceschi","year":"2001","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N","article-title":"Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism","volume":"47","author":"Grimaldi","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib12","doi-asserted-by":"crossref","unstructured":"Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol; 2005.","DOI":"10.1038\/ncb1313"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib13","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","article-title":"Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease","volume":"345","author":"in t\u2019 Veld","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib15","doi-asserted-by":"crossref","first-page":"65K","DOI":"10.1016\/j.amjcard.2005.08.011","article-title":"Pharmacogenomics of statin responsiveness","volume":"96","author":"Kajinami","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jnr.10253","article-title":"Cytokines, chemokines, and cytokine receptors in human microglia","volume":"69","author":"Lee","year":"2002","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0047-6374(03)00034-4","article-title":"Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background","volume":"124","author":"Licastro","year":"2003","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib18","first-page":"2","article-title":"Innate immunity and inflammation in ageing: a key for understanding age-related diseases","volume":"18","author":"Licastro","year":"2005","journal-title":"Immun Ageing"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0165-5728(99)00226-X","article-title":"Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?","volume":"103","author":"Licastro","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/1531-8249(200009)48:3<388::AID-ANA16>3.0.CO;2-G","article-title":"Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk","volume":"48","author":"Licastro","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-5728(98)00096-4","article-title":"Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype","volume":"88","author":"Licastro","year":"1998","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0197-4580(03)00013-7","article-title":"Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain","volume":"24","author":"Licastro","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0167-4943(01)00143-1","article-title":"Genetic background of inflammatory molecules affects protein expression, the risk of developing Alzheimer's disease and cognitive decline","volume":"7","author":"Licastro","year":"2001","journal-title":"Arch Gerontol Geriatr Suppl"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.neurobiolaging.2004.05.001","article-title":"A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease","volume":"26","author":"Licastro","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3940(99)00468-1","article-title":"Apolipoprotein E and alpha-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease","volume":"270","author":"Licastro","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib26","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/01.WNL.0000142963.90204.58","article-title":"Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study","volume":"63","author":"Li","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.gene.6363964","article-title":"Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease","volume":"4","author":"Lio","year":"2003","journal-title":"Genes Immun"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0531-5565(98)00013-8","article-title":"The importance of inflammatory mechanisms in Alzheimer disease","volume":"33","author":"McGeer","year":"1998","journal-title":"Exp Gerontol"},{"issue":"7","key":"10.1016\/j.neurobiolaging.2006.07.007_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.npp.1300668","article-title":"Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models","volume":"30","author":"Morihara","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nn0403-345","article-title":"Alzheimer's disease: the cholesterol connection","volume":"6","author":"Puglielli","year":"2003","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.10265","article-title":"Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study","volume":"52","author":"Schmidt","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneur.62.5.753","article-title":"Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results","volume":"62","author":"Sparks","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib35","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0002-9440(10)63269-5","article-title":"Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease","volume":"165","author":"Sung","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib36","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","article-title":"Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors","volume":"57","author":"Wolozin","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/01969727408621685","article-title":"Clinical pure types as a fuzzy partition","volume":"4","author":"Woodbury","year":"1974","journal-title":"J Cybernetics"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archpsyc.62.2.217","article-title":"Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study","volume":"62","author":"Zandi","year":"2005","journal-title":"Arch Gen Psychiatr"},{"key":"10.1016\/j.neurobiolaging.2006.07.007_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2318-5-2","article-title":"Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study","volume":"5","author":"Yip","year":"2005","journal-title":"BMC Geriatr"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458006002594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458006002594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T21:00:53Z","timestamp":1555794053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458006002594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0197458006002594"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2006.07.007","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}